Robert Andersen, MD
Urology · Owensboro, KYNPI 1588617427
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 266 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,091, 5.5 times the $381 reported in 2019.
Across 266 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Pfizer$583
- Astellas Pharma US Inc$541
- Sumitomo Pharma America, Inc.$468
- Endo USA, Inc.$387
- AbbVie$271
- plus $3K from 31 others
What the payments were for
- Food & beverage$5,42692%
- Education$4418%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(3 entities) | 41 | $1,041 |
| Pfizer | 32 | $583 |
| Astellas Pharma US Inc | 26 | $541 |
| Sumitomo Pharma America, Inc. | 23 | $468 |
| Endo USA, Inc. | 14 | $387 |
| AbbVie | 16 | $271 |
| C. R. Bard, Inc. & Subsidiaries | 17 | $269 |
| 180 Medical, Inc. | 12 | $262 |
| Endo Pharmaceuticals Inc. | 9 | $242 |
| Urogen Pharma, Inc. | 9 | $208 |
| Procept Biorobotics Corporation | 3 | $155 |
| Tolmar, Inc. | 8 | $145 |
| Boston Scientific | 4 | $144 |
| Teleflex LLC | 6 | $126 |
| Dendreon Pharmaceuticals LLC | 4 | $125 |
| Immunitybio, Inc. | 6 | $109 |
| Progenics Pharmaceuticals, Inc. | 2 | $91 |
| Merck | 5 | $84 |
| Blue Earth Diagnostics | 3 | $71 |
| Novartis | 3 | $58 |
| KARL Storz Endoscopy-america | 1 | $56 |
| Calyxo, Inc. | 2 | $49 |
| Olympus America Inc. | 2 | $42 |
| Bard Access Systems, Inc. | 1 | $42 |
| Medtronic | 1 | $37 |
| Axonics, Inc. | 2 | $36 |
| Myriad Genetic Laboratories, Inc. | 2 | $32 |
| Bioprotect Medical, Inc. | 2 | $32 |
| Biotissue Holdings Inc. | 1 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Foundation Medicine, Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Photocure Inc | 1 | $14 |
| Dentsply IH Inc. | 1 | $13 |
| Coloplast | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBREVANT$144
- CARVYKTI$144
- AquaBeam Robotic System$107
How this compares
$5,867 in reported general payments places this provider in the 70th percentile of 139 urology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 49 | $45,373 |
| GemtesaVibegron | 23 | $29,713 |
| Finasteride | 710 | $8,999 |
| Tamsulosin Hcl | 661 | $7,157 |
| Trimethoprim | 55 | $4,611 |
| Methenamine Hippurate | 53 | $3,647 |
| Estradiol | 27 | $3,641 |
| Potassium Citrate ErPotassium Citrate | 47 | $2,773 |
| Cephalexin | 315 | $2,698 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 70 | $1,617 |
| Dutasteride | 43 | $1,214 |
| Oxybutynin Chloride ErOxybutynin Chloride | 45 | $1,201 |
| Cefpodoxime Proxetil | 19 | $1,193 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $1,153 |
| Bicalutamide | 22 | $787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $541 | $45,37349 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $468 | $29,71323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 139 urology providers in Kentucky.
Other urology in Owensboro
- Corey JohnsonOwensboro$10K
- Daniel WarburtonOwensboro$8K
- Thomas SlabaughLexington$102K
- Uzoma AneleLouisville$60K
- Lee EvansHopkinsville$56K
- Patrick HensleyLexington$50K
- Brooke EdwardsCrestview Hills$45K
- Robert LarkeCrestview Hills$22K
- Stephen MonnigLexington$18K
- Kellen ChoiLouisville$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.